PubRank

Lori A Hazlehurst

Author PubWeight™ 22.38‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008 3.50
2 Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 2008 1.65
3 Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009 1.55
4 Proteomic contributions to personalized cancer care. Mol Cell Proteomics 2008 1.46
5 The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 2005 1.43
6 Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 2009 1.25
7 Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood 2007 1.23
8 Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res 2009 1.12
9 HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells. Mol Cancer Ther 2009 0.99
10 The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol 2010 0.96
11 CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo. J Cancer 2013 0.94
12 Role of STAT3 in Transformation and Drug Resistance in CML. Front Oncol 2012 0.89
13 Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML. Leuk Res 2011 0.88
14 Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype. Mol Cancer Ther 2011 0.86
15 Emerging strategies for targeting cell adhesion in multiple myeloma. Adv Pharmacol 2012 0.85
16 Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. J Med Chem 2013 0.85
17 Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels. J Pharmacol Exp Ther 2011 0.83
18 The one-two punch: combination treatment in chronic myeloid leukemia. Crit Rev Oncol Hematol 2013 0.80
19 MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma. Mol Cancer Ther 2013 0.79